Home
/
NowPatient Blog
/
Everything You Need to Know About The New Hair Loss Treatment PP405

Everything You Need to Know About The New Hair Loss Treatment PP405

Stefano Mirabello NowPatientGreen tick
Medically reviewed by Stefano Mirabello, B.Pharm
Written by Rajive Patel, B.Pharm
Created on 30 Jul 2025
Updated on 30 Jul 2025

Before we get into the pipeline of new drugs that can treat hair loss, it’s a good idea to refresh yourself with what the five type of hair loss are:

  • Androgenetic Alopecia (female and male pattern baldness). This is by far the largest type of hair loss and is responsible for 90% of all cases of hair loss.
  • Chemotherapy. As the name suggests, this is hair loss induced by cancer treatment
  • Telogen effluvium. This is stress-induced hair loss
  • Alopecia Areata. This is auto-immune induced hair loss
  • Scarring Alopecia. This is hair loss from scalp injury

The need for newer and better hair loss treatments

Hair loss, especially androgenetic alopecia, affects millions of men and women worldwide. While traditional therapies like minoxidil and finasteride (Propecia) have been available for decades, these treatments are generally viewed as being limited and fall short of patient expectations for full, permanent hair restoration. Additionally, they generally require lifelong commitment and come with potential side effects. The good news is that there are a number of pharmaceutical companies pushing through with novel hair loss treatments.

Learn more about common treatments

scrollable

New Hair Loss Treatments by Clinical Trials Stages and Target Hair Loss Condition

New Hair Loss Treatments by Clinical Trials Stages and Target Hair Loss Condition

Is PP405 the Answer to Hair Loss?

A promising new topical small-molecule compound, PP405, has emerged as a frontrunner in the race for a newer and better treatment for hair loss. It can spark new hair growth by directly stimulating human hair follicle stem cells.

Developed by Pelage Pharmaceuticals, a medical development company spun out of research at UCLA, PP405 is now in Phase 2a human trials for the treatment of androgenetic alopecia.

Early data suggests it may offer a breakthrough for not only for male pattern baldness but also for patients affected by medical conditions such as chemotherapy-induced hair loss.

What is PP405?

PP405 is a topical small molecule that bypasses hormonal pathways and targets metabolic signaling inside the follicle. Specifically, it inhibits the mitochondrial pyruvate carrier (MPC), which is a protein that controls how pyruvate enters the mitochondria for energy generation.

By disrupting this pathway, PP405 shifts cells toward glycolysis, a state that promotes hair regeneration.

The compound was developed by UCLA scientists, including Dr. Heather Christofk, a professor of biological chemistry, and Dr. William Lowry, a stem cell biologist. Their work featured in UCLA Magazine and, based on earlier findings at Harvard Medical School, has been pivotal in uncovering how metabolism controls stem cell activation.

Check out their phase 1 clinical study.

How Does PP405 Work?

Think back to the burn in your legs during a hard workout; that’s your muscles switching from oxygen-powered (aerobic) metabolism to glycolysis, a faster, oxygen-independent way of producing energy.

Interestingly, regenerating hair follicle stem cells prefer this same shortcut.

Instead of relying on the mitochondria, they thrive in a glycolytic state, just like your muscles during sprints. It’s not about energy efficiency, it’s about speed and readiness to grow.

PP405 mimics this state.

By blocking the mitochondrial pyruvate carrier (MPC), PP405 nudges dormant hair follicle stem cells away from mitochondrial metabolism and into glycolysis, triggering them to exit dormancy and start regenerating.

PP405 reawakens dormant hair follicles by forcing cells into glycolysis.

PP405 reawakens dormant hair follicles by forcing cells into glycolysis.

How Does PP405 Affect the Hair Growth Cycle?

PP405 interacts with the hair cycle by targeting the transition from the telogen (resting) phase to the anagen (growth) phase, thereby reactivating dormant follicles in patients experiencing pattern hair loss. In inhibiting the mitochondrial pyruvate carrier (MPC), energy production within hair follicle stem cells shifts toward glycolysi,s which is a metabolic state associated with tissue regeneration. This reprogramming promotes hair follicle regeneration and initiates a return to active growth, accelerating the anagen phase and stimulating visible hair regrowth.

July 2025 PP405 Study Update

In the July 2025 trial update, the randomized portion of the PP405 Phase 2a clinical trial progressed with updated eligibility and inclusion criteria, refining participant selection for improved consistency.

The study’s sponsor, Pelage Pharmaceuticals, reported that the trial met its primary safety endpoint, with no significant adverse events reported.

The investigational treatment, which presents as a 0.05% topical ge,l demonstrated promising results in men with more advanced androgenetic alopecia. 31% of those trial participants achieved over 20% improvement in their hair density at 8 weeks, compared to 0% in the placebo group.

Dr. Arash Mostaghimi, Vice Chair of Clinical Trials and Innovation at Brigham and Women’s Hospital, emphasized the scientific rigor of the study design and noted that PP405 demonstrated measurable biological activity early in treatment. In August 2024, Dr. Mostaghimi was also appointed to the Clinical Advisory Board of Pelage Pharmaceuticals, strengthening his advisory role in the advancement of this regenerative hair loss therapy.

The study includes both male and female participants, helping to ensure broader applicability across biological sexes. Ongoing quality control (QC) review is in progress, with the clinical record last updated in July 2025 on ClinicalTrials.gov.

The study is estimated to complete in December 2025.

Understanding the Science Behind PP405

Hair follicles cycle through growth, rest, and shedding phases. When human hair follicle stem cells become quiescent, often due to aging, metabolic imbalance, or damage, then hair stops regenerating.

A 2017 hair loss study in Nature Cell Biology found that increasing lactate dehydrogenase measurable biological activity, could reactivate stem cells, promoting regrowth (Flores et al., 2017). PP405’s mechanism of action mimics this by shifting energy usage in stem cells.

Understanding FDA Clinical Trial Phases

For a new pharmaceutical like PP405 to reach the public in the United States, it must undergo a multi-phase review process overseen by the U.S. Food and Drug Administration (FDA). Each phase is designed to assess the drug’s safety, the effect of intervention, dosage, and side effect profile in progressively larger and more diverse patient populations.

  1. Phase 1: The initial phase evaluates basic safety, tolerability, and pharmacokinetics in a small group of healthy volunteers or patients.
  2. Phase 2a: Focuses on finding the ideal dosage range and early evidence of effectiveness in a target population.
  3. Phase 2b: Further investigates efficacy and safety in a larger cohort.
  4. Phase 3: Large-scale, multicenter trials to compare the drug against placebo or a different drug that is used as current standard of care before potential approval.

PP405 is currently in Phase 2a, which focuses on collecting data on dosage and early signs of efficacy. Its future progression and licensing potential depends on whether favorable data analysis persists on in rigorous future studies.

PP405 and its regulatory journey (FDA)

PP405 and its regulatory journey (FDA)

What are the chances that PP405 for Hair Loss Drugs will fail?

Regulatory approval is a long and demanding journey. While PP405 shows promise, many hair loss drugs have stalled or been abandoned in their clinical development cycle. Below is a table showing the status of the current raft of hair loss treatments

Table representing PP405

PP405 will need to prove itself in long-term, multicenter trials before there can be clarity on the likelihood of it being licensed by the FDA or other regions like UK’s MHRA or EU’s EMA.

Medical Disclaimer

NowPatient has taken all reasonable steps to ensure that all material is factually accurate, complete, and current. However, the knowledge and experience of a qualified healthcare professional should always be sought after instead of using the information on this page. Before taking any drug, you should always speak to your doctor or another qualified healthcare provider.

The information provided here about medications is subject to change and is not meant to include all uses, precautions, warnings, directions, drug interactions, allergic reactions, or negative effects. The absence of warnings or other information for a particular medication does not imply that the medication or medication combination is appropriate for all patients or for all possible purposes.

Now Patient Data Security

Trusted and certified to keep your data safe.

Learn moreNow Patient Data Security
Now Patient Data Security

Can I Trust NowPatient

Our product and services are certified to international healthcare, medical device and data security standards

  • Class 1 Medical Device

Medicines Experts

Meet our medical team

WHY WE BUILT NOWPATIENT

We are committed to helping everyone, everywhere live healthier lives

The NowPatient virtual care platform provides you with access to trusted health information, affordable treatments, management of chronic health conditions and continuous monitoring for health risks. NowPatient can be accessed by downloading the App or using your web browser.

Download our app today

Nowpatient homepage

Your Questions Answered

For your peace of mind, we can answer your questions quickly

What does NowPatient do?

NowPatient is a digital health-technology platform functioning as both an online pharmacy and telehealth service. Packaged as a Class I software medical device, it’s accessible via web browser or mobile app (iOS and Android), and offers users worldwide on-demand access to virtual consultations, prescription services, and AI-powered health tools.

What It Does

    • NHS Online Pharmacy: Order NHS-approved prescriptions (UK)
    • Drug Savings: Access major US drug-savings programs (coupons, savings cards, manufacturer assistance, Canadian drug savings).
    • Virtual Consultations: Get treated for a wide range of medical conditions by expert clinicians using a secure telehealth link.
    • Medication Management: Set up refill & dose reminders, view private treatment plans, and track chronic conditions like diabetes or hypertension.
  • Health-Monitoring Tools: Use AI-driven assessments for genetic risk tests, home test kits and blood-pressure monitoring.
  • Wellness Insights: Access real-time pollen counts, air-quality data, BMI and type 2 diabetes risk scores, plus comprehensive health-condition information.

Get started today and benefit from Medication RemindersGet Treated PrivatelyNHS Online PharmacyGP Appointment BookingRx Savings CardDrug CouponsUS Drug Savings ProgramsHealth Conditions InformationGenetic TestingHome Test KitsBMI RisksType 2 Diabetes RisksPollen MeterAir Quality Monitor, and lots more!

Our service is operated by experienced medical professionals in the United States and the United Kingdom.

You can view the online services we provide by clicking the link below:

Features

Where is NowPatient located?

NowPatient has offices in the United Kingdom and United States.

In the UK, we are located at:

NowPatient
28 Chipstead Valley Road
Coulsdon
Surrey
CR52RA

In the US, we are located at:

NowPatient
8911 North Capital of Texas Highway
Suite 4200 #1263
78759
Austin, TX

How can I contact NowPatient?

To contact NowPatient, please use the contact form available on the Contact Us page.

Alternatively, if you need to speak to us, you can reach us on the following numbers:

UK telephone number – 020 388 51 500
US telephone number – 1-866-967-1977

Who owns NowPatient?

NowPatient is owned and operated by Infohealth Ltd, a licensed online pharmacy with services spanning the UK, US and Rest of the World. Infohealth Ltd is registered in England and Wales under company number 04004930 and our registered office is at Lynwood House, 373 – 375 Station Road, Harrow, England, HA1 2AW.

Our website is www.nowpatient.com. Our App is called “NowPatient” and can be downloaded from the App Store (for Apple devices) or Google Play (for Android devices).

Can you tell me more about your NHS online pharmacy?

NowPatient’s Pharmaceutical services in the UK are provided by Infohealth Limited trading as ‘Infohealth Pharmacy’.

Our dispensing pharmacy is regulated and authorized for internet sales by the General Pharmaceutical Council (GPhC), registration number 1036487. You can view our license credentials on the General Pharmaceutical Council website. Our superintendent pharmacist who is responsible for the safe and effective oversight of medicines supplies is Mr Amish Patel (Registration Number 2042705).

Medicines are not ordinary items of commerce. All medicines or healthcare product sales are made under the supervision of a registered pharmacist who is licensed by the GPhC. At all times, we endeavour to provide a professional and transparent service whose primary goal is to ensure that the best interests of the patient are served.

How do I make a complaint?

From time to time, we accept that our service levels may not be up to your expectations. NowPatient welcomes concerns, compliments and complaints as valuable feedback that will help us learn from your experiences and make improvements. Feedback can be provided via our clear and transparent Complaints Procedures.

Can you tell me more about NowPatient’s prescribing services for treatments offered?

Our prescribing services are regulated by the General Pharmaceutical Council (GPhC). We provide the following regulated activity:

• treatment of disease, disorder, or injury
• transport services, triage, and medical advice are provided remotely
• caring for adults over 65 years old
• caring for adults under 65 years old

NowPatient prescribing services are run by Infohealth Limited. The Clinical Safety Officer and nominated individual is Mr Navin Khosla.

Can you tell me more about NowPatient’s US services?

Our head of US services is Dr. Jamie Winn.

You can lower the cost of your prescription medications using our various savings programs which include drug coupons, savings card and manufacturer-sponsored patient assistance programs.

What are the steps to booking a live video consultation?

Follow the steps below to book a consultation:

If I place an order, how do I check out?

Follow the steps below to checkout:

Is NowPatient legit and can I trust information from NowPatient?

Yes. NowPatient provides trustworthy and accessible clinical, health education and prescription services. We are also trusted by the NHS to deliver clinical and NHS repeat prescription dispensing across the whole of England. In the United States, we work with over 65,000 pharmacies to deliver considerable costs savings for our users.

NowPatient is operated by experienced licensed medical professionals in the United Kingdom and United States. Our Medical Team can be found here.

Our service is trusted by thousands of patients worldwide. You can read their reviews on our Trustpilot:

NowPatient Trustpilot

Does NowPatient have insurance in place for the services it provides?

Yes. NowPatient is fully insured to provide pharmacy & prescribing services. Insurance not only provides peace of mind but also provides an effective safety net for both you and our clinicians.

Why is it important to choose an online pharmacy and telehealth service that is insured?

Insurance is more than just a financial safeguard, it is a signal of legitimacy and accountability.

We insure our services, so that it:

  • Shows you that we are compliant with all laws and industry standards in the markets that we operate.
  • Shows you that we are committed to standards of professionalism.
  • Reinforces your confidence that you are dealing with a reputable provider.

Who insures your services and which services are insured?

We are insured by the National Pharmacy Association in the UK.

The scope of the services covered include:

  • dispensing of prescriptions
  • telehealth prescribing services.

In addition, all of the clinicians that operate on our platform have their personal indemnity insurance & scope of clinical practice validated and checked before they are able to provide services.

What are NowPatient’s opening hours?

Our office hours are:

UK – Monday-Friday 9am-6pm GMT
US – Monday-Friday 8am-5pm EST

Please note that we are closed at weekends.

In the event of a medical life-threatening emergency please call:

UK – 999
US – 911

In the event of a medical emergency which is not life-threatening please call:

UK – 111